Muntner, Paul
Ghazi, Lama http://orcid.org/0000-0002-9930-3575
Jones, Jenna
Dhalwani, Nafeesa
Poudel, Bharat
Wen, Ying
Chen, Ligong
Wang, Zhixin
Bittner, Vera
Kalich, Bethany
Farkouh, Michael E.
Woodward, Mark
Colantonio, Lisandro D.
Rosenson, Robert S.
Funding for this research was provided by:
Amgen
Article History
Received: 1 February 2024
Accepted: 4 April 2024
First Online: 30 April 2024
Declarations
:
: Paul Muntner is an employee of the US Centers for Disease Control and Prevention. This work was conducted while he was at the University of Alabama at Birmingham, and the findings and conclusions in this report are those of the authors and do not necessarily reflect the Centers for Disease Control and Prevention. Lama Ghazi and Lisandro D. Colantonio receive research support from Amgen Inc. Jenna Jones, Nafeesa Dhalwani and Bethany Kalich are employee and stockholders of Amgen Inc. Vera Bittner receives research grants to her institution from Sanofi and Regeneron (ODYSSEY OUTCOMES trial, Steering Committee member), Esperion (CLEAR OUTCOMES trial, National Coordinator), Dalcor (DalGene trial, National Coordinator), Astra Zeneca (STRENGTH trial, National Coordinator), Novartis (ORION trial, Site PI) and Amgen (Industry Collaboration between the UAB School of Public Health and Amgen, co-Investigator). Vera Bittner also receives or received payments as Senior Guest Editor for Circulation (American Heart Association, ongoing), Editor in Chief of the American College of Cardiology Self-Assessment Program (ACCSAP, American College of Cardiology, ongoing), Advisory Board member (Pfizer, concluded at the end of 2021) and Data Safety Monitoring Board member (Verve Therapeutics, ongoing). Mark Woodward was recently a consultant to Amgen and Freeline. Robert S. Rosenson receives research grants to his institution from Amgen, Arrowhead, Eli Lilly, NIH, Novartis and Regeneron; consulting fees from Amgen, CRISPER Therapeutics Eli Lilly, Lipigon, Novartis, Precision Biosciences, Regeneron, UltraGenyx and Verve; non-promotional honoraria from Kowa; royalties from Wolters Kluwer (UpToDate); stock holding in MediMergent, LLC; and patent applications on: Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device (EFS ID: 32278349, Application No. PCT/US2019/026364, provisional); Compositions and methods relating to the identification and treatment of immunothrombotic conditions (New International Application No. PCT/US2021/63104926), and Quantification of Lp(a) vs. non-Lp(a) apoB concentration: development of a novel validated equation. (Application No. PCT/US2021/63248837). Bharat Poudel, Michael E. Farkouh, Zhixin Wang, Ligong Chen and Ying Wen report no disclosures.
: Approval for this analysis was obtained from the Institutional Review Board at the University of Alabama at Birmingham. All data used in this analysis were collected as part of routine medical care. The requirement to obtain informed consent for this analysis of de-identified data was waived by the Institutional Review Board at the University of Alabama at Birmingham. Marketscan data were licensed from International Business Machines Corporation (Armonk, NY), and Medicare data were licensed from the US Centers for Medicare and Medicaid Services (CMS) Chronic Conditions Warehouse.